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During the last decades, since 1996, there 
has been a strong commitment to reach 
both therapeutic efficacy and avoidance of 
drug resistance in case of virologic failure. 
The development of modern drug classes 
has facilitated the life of those involved 
in HIV/AIDS treatment, particularly 
HIV-infected subjects. There is still a 
gap between the perfect efficacy and the 
maximal adherence and tolerability, and of 
course all three aspects are interconnected.
It is very clear that there is a distinct rela-
tionship between the degree of adherence 
to the antiretroviral (ARV) medications 
and the virologic suppression. This was 
initially demonstrated by the ARV regimen 
during the first highly active ARV therapy 
(HAART) era and has been confirmed more 
recently with combination drugs, including 
non-nucleoside reverse-transcriptase inhibi-
tors (NNRTI). The optimal cut-off is, again, 
the 95% adherence [1]. In both developing 
and developed countries there have been 
many demonstrations on how adherence 
affects clinical outcomes. Such an example 
comes from the the AIDS support organiza-
tion initiative in Uganda: data show that, 
even within the first year and a half of ARV 
therapy, there is a significant difference, of 
approximately 40%, in survival between 
adherent and nonadherent subjects [2]. In 
the MACS cohort [3], ≥80% suppression 
was observed with 80–84% adherence 
and the odds ratio for suppression versus 
≥95% adherence was 1.43 (0.61,3.33). In 
the ALIVE study [4], where <35% were on 
newer drugs, only 71.4% were suppressed 
among those who reported ≥95% adher-
ence. This suggests concerns related to 
nonadherence may be less of a barrier to the 
initiation of modern HAART regimens [5]. 
In the ICONA cohort, nonadherence was 
responsible for only 2% of treatment dis-
continuation in HIV-1 infected individuals 
starting their first-line ARV regimen after 
2008 in Italy [6].
Nonadherence rates improve over time 
with the extension of follow-up visits, 
as shown by the CAPRISA initiative in 
South Africa. The nonadherence rate was 
>40% at the initial visit and decreased to 
roughly 15% at visit 17 [7]. HAART adher-
ence levels for individuals who started 
therapy in British Columbia increased over 
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“It is very clear that there is a distinct 
relationship between the degree of adherence 
to the antiretroviral medications and the 
virologic suppression.”
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time during 1996–2012. While only 37% of 
individuals had adherence levels ≥95% in 1996, 
this increased to 71% for individuals (p = 0.0032) 
by 2012 [8]. There is a tight interplay between 
adherence and virological suppression, and drug 
resistance, as shown by the work of Nachega et al. 
Lower pill burden was significantly associated with 
both better adherence and virological suppression 
in 19 studies including 6312 adult patients [9]. 
Likely due to safer and more effective drugs and 
an improvement in patient’s adherence, recent 
data dealing with the epidemiology of resistance 
to ARVs showed a declining prevalence of HIV-1 
drug resistance in experienced individuals in 
Western Europe (SEHERE collaboration) with 
the exception of NNRTI [10]. The proportion with 
extensive three-class resistance over calendar years 
by the last and the cumulative genotype decreased 
between 2005 and 2008 and the proportion of 
cases with an exhaustion of drug options by 
the last and the cumulative genotype was <5% 
in 2008 [10].
When we think about drug resistance, the 
paradigmatic view ranges from an easy prob-
ability of developing drug resistance, detected 
via minority variants methods, id est, resistance 
toward NNRTI and the extent of cross-resist-
ance to newer compounds. An example of the 
first dynamic is the low frequency of NNRTI 
mutations K103N, Y181C and NRTI mutations 
M184V, K65R, and the risk of NNRTI-based 
ARV treatment failure. Minority drug-resistant 
variants were found in 14% of samples in this 
systematic review [11]. The second example is illus-
trated by the resistance to the newest ARV class, 
which is well established in the clinical arena: the 
integrase inhibitors (INI). A recent report from 
the USA underlines that one out of five patients 
tested during the first 3 years of the availability 
of a genotypic resistance test for INI harbored at 
least one major integrase-resistance mutation [12]. 
The positive aspect of the resistance to INI is that 
cross-resistance between raltegravir, or elvitegravir, 
and dolutegravir is very contained in raltegravir-
naive patients. In raltegravir-pretreated patients, 
50 (41.7%) of the integrase sequences obtained at 
failure of raltegravir therapy did not contain any 
mutation at codons 143, 148 and 155 [13].
A totally different story may be told in the 
upcoming scenario of long-acting (LA) com-
pounds, that is, cabotegravir and rilpivirine that 
can be administered via a subcutaneous or intra-
muscular injection. These compounds possess a 
very long half-life, thus can resolve most of the 
problems connected with adherence. But there 
are still missing spots: we have no data regard-
ing the virologic protection after the final injec-
tion of these compounds. If a patient withdraws 
from a trial, will the pharmacological ‘tail’ still 
be protective or pose a serious threat for the 
development of drug resistance? A single case 
of an emergent NNRTI-resistant virus has been 
reported in a subject from a rilpivirine LA 300 mg 
Phase I tissue pharmacokinetic study [14]. The LA 
pharmacokinetics may not be sufficient in non-
adherent patients and consequences of this insuf-
ficient drug exposure could appear later on, with-
out being adjustable thus jeopardizing patient’s 
therapeutics [15].
Thus, there is still an ongoing debate on situ-
ations when the maximal virologic efficacy is 
essential and maximizing drug adherence is a 
priority. In the near future, more friendly drug 
regimens/administration devices will help in 
maintaining optimal therapeutic results and 
keeping regimen forgiveness at the highest level.
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